Dr. Alex Herrera (IMAGE)

SWOG Cancer Research Network

Dr. Alex Herrera

Caption

Nivolumab added to AVD chemotherapy halved the risk of remission or death in the first year compared to standard BV-AVD therapy in adolescents and adults with advanced stage classic Hodgkin lymphoma. Dr. Alex Herrera of City of Hope presents these results from the SWOG Cancer Research Network's S1826 clinical trial at the plenary session of the American Society for Clinical Oncology (ASCO) 2023 annual meeting.

Credit

City of Hope

Usage Restrictions

Credit City of Hope

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.